Navigation Links
Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
Date:9/15/2009

SAN DIEGO, Sept. 15 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that new data highlighting fidaxomicin's (OPT-80) lower CDI recurrence rates and reduced risk of vancomycin-resistant enterococci (VRE) acquisition from Optimer's North American phase 3 study were presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco.

(Logo:http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

"The additional data highlight fidaxomicin's unique profile as a new antibiotic class with beneficial characteristics for treating CDI," said Michael N. Chang, Ph.D., President and CEO of Optimer Pharmaceuticals. "These analyses describe fidaxomicin's low recurrence rate, safety profile, potent activity against CDI, and minimal disruption to the normal intestinal flora. We think fidaxomicin has the potential to be the treatment of choice for CDI which is a serious unmet medical need with limited treatment options."

Yoav Golan, M.D., an investigator from the Tufts Medical Center in Boston, MA, presented additional analyses around the previously reported recurrence data showing that patients treated with fidaxomicin had a substantially lower recurrence rate (13.3%) than those treated with vancomycin (24.0%). However, the recurrence rate difference between fidaxomicin and vancomycin was even greater, 10.9% versus 24.3%, respectively, in patients who did not receive CDI therapy (either vancomycin or metronidazole) in the 24-hour pre-trial enrollment period. Dr. Golan further noted that CDI recurrence occurred significantly later in patients t
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ISELIN, N.J. , July 1, 2015 /PRNewswire/ ... medical device company focused on non-invasive continuous glucose ... of its new and completely re-designed corporate website ... and intuitive access to Echo,s technology and enhances ... The new website better communicates to prospective ...
(Date:7/1/2015)... , July 1, 2015 Prismic Pharmaceuticals, ... and FDA-regulated medical foods, today announced the election of ... Simonetti to its Board of Directors. ... members, Peter Moriarty , Chairman and CEO of ... and Martin Simonetti have accepted our ...
(Date:7/1/2015)... July 1, 2015  Unilife Corporation (NASDAQ: UNIS ... of injectable drug delivery systems, announced today that its ... June 30, 2015. This amendment removed a covenant that ... cash receipts from customers during the six months ended ... any of the terms of the debt agreement as ...
Breaking Medicine Technology:Echo Therapeutics Announces New Website Launch 2Echo Therapeutics Announces New Website Launch 3Joseph Krivulka and Martin Simonetti Join Board of Prismic Pharmaceuticals 2Unilife and OrbiMed Amend Debt Financing Agreement 2Unilife and OrbiMed Amend Debt Financing Agreement 3
... , WASHINGTON, Dec. 10 BioWorld Today ... Research and Manufacturers of America ( PhRMA ) that identifies 97 new ... conditions. , The report , which was released ahead of ... found that the 97 products in development include 23 vaccines and 54 ...
... , MILFORD, Mass., Dec. 10 ... that it is partnering with the NC BioNetwork Pharmaceutical ... NC, to educate and train students and workers in ... biopharmaceutical industry. The Pharmaceutical Center, which is a collaborative ...
Cached Medicine Technology:Nearly 100 HIV/AIDS Drugs and Vaccines in Development Pipeline 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 4
(Date:7/1/2015)... ... 01, 2015 , ... With all final regulatory approvals in ... Syracuse, N.Y., is now a member of national system Trinity Health, effective immediately. ... partner committed to delivering high-value care, said Richard J. Gilfillan, M.D., president and ...
(Date:7/1/2015)... , ... July 01, 2015 , ... Sir Fazle Hasan ... World Food Prize today. Sir Fazle has been recognised for his outstanding contribution to ... , Ambassador Ken Quinn, President of the World Food Prize Foundation, announced this year’s ...
(Date:7/1/2015)... , ... July 01, 2015 , ... For decades, researchers ... wound, histones, remain constant in the brain, never changing after development in the womb. ... histones are steadily replaced in brain cells throughout life – a process which helps ...
(Date:7/1/2015)... ... July 01, 2015 , ... The Lymphoma Research Foundation ... research and serving the lymphoma community through a comprehensive series of education programs, ... new members to their industry leading Scientific Advisory Board. LRF’s volunteer Scientific Advisory ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... ... technology and services, today announced that its fifth annual Smile for a Lifetime ... $80,000 for the non-profit organization. In addition to supporting S4L in its mission ...
Breaking Medicine News(10 mins):Health News:St. Joseph’s Health Now a Member of Trinity Health 2Health News:St. Joseph’s Health Now a Member of Trinity Health 3Health News:St. Joseph’s Health Now a Member of Trinity Health 4Health News:Sir Fazle Hasan Abed Receives World Food Prize 2Health News:Sir Fazle Hasan Abed Receives World Food Prize 3Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 2Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 3Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 4Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 2Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 3Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 4Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 5Health News:The Forum Fundraiser Raises $80,000 for the Smile for a Lifetime Foundation 2Health News:The Forum Fundraiser Raises $80,000 for the Smile for a Lifetime Foundation 3
... costs drop by one-third, study finds , SATURDAY, Jan. ... costs in children with hay fever by one-third and ... 10-year U.S. study. , Researchers compared the medical ... who received allergy vaccinations with the claims of 11,000 ...
... ... the cost of their Diabetes Panel to $89 for the month of January. Symptoms of ... your hands or feet. , ... TX (Vocus) January 16, 2010 -- ANY LAB TEST NOW North Dallas locations have lowered the ...
... , Jan. 15 Kaiser Permanente announced today ... disaster relief organizations to provide aid to the victims of ... care organization has wired the funding to Doctors Without Borders, ... expertise and support to U.S. disaster response teams. , "Our ...
... Calif., Jan. 15 Dr. Richard Merkin , President ... sending much needed assistance to the Haitian earthquake victims through the Haiti ... leaving Jan 25 & 26. The fund will house 200 ... hundreds of patients a day at their clinic. The Haiti Endowment Fund ...
... , OAKLAND, Calif. , Jan. 15 Nearly 7,500 ... disaster relief,  believed to be the largest outpouring of RN volunteers in ... working around the clock to find locations for the nurses to deploy ... signing up through the NNU program as well. , View ...
... , SOUTHFIELD, Mich. , Jan. 15 ... the American-based relief organization, Life for Relief and Development (Life) in ... (MBRMC), a prominent humanitarian relief organization in the United ... campaign for the victims of the recent earthquake in Haiti ...
Cached Medicine News:Health News:Shots Relieve Children's Hay Fever, Cut Expenses 2Health News:ANY LAB TEST NOW North Dallas Lowers Diabetes Testing to $89 2Health News:Kaiser Permanente Donates $500,000 for Relief Efforts Following Earthquake in Haiti 2Health News:Kaiser Permanente Donates $500,000 for Relief Efforts Following Earthquake in Haiti 3Health News:Heritage Provider Network, Dr. Richard Merkin, Comes to the Aid of Haitian Earthquake Victims 2Health News:Nearly 7,500 RNs Ready to Deploy to Haiti 2Health News:Life for Relief & Dubai Charity to Send $1.25 Million in Emergency Relief for Haiti Earthquake Victims 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: